Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk
BioPharma Dive
After winning the battle for injectable obesity medicines, Lilly hopes Foundayo can help it catch up in the oral market, where Novo has a three-month lead.
pharminent
April 9, 2026 (Last updated: April 9, 2026)
BioPharma Dive
After winning the battle for injectable obesity medicines, Lilly hopes Foundayo can help it catch up in the oral market, where Novo has a three-month lead.
